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OBJECTIVES This prospective randomized study investigated platelet-induced upregulation of Mac-1 on
monocytes and its inhibition by glycoprotein (GP) IIb/IIIa blockage in patients with acute
myocardial infarction (AMI).
BACKGROUND In experimental AMI, Mac-1 on leukocytes is the pivotal adhesion molecule for detrimental
inflammatory responses. In vitro, platelet adhesion to monocytes upregulates Mac-1.
METHODS Patients undergoing stenting in AMI within 48 h after onset of symptoms were randomly
assigned to receive either standard-dose heparin (n 5 50) or abciximab plus low-dose heparin
(n 5 50). In serial blood samples, we assessed platelet-monocyte interaction and Mac-1
surface expression by triple color immunofluorescence flow cytometry.
RESULTS Compared with platelet-negative monocytes, Mac-1 surface expression on monocytes with
attached platelets was upregulated (median fluorescence intensity [interquartile range]: 259
[179 to 367] vs. 135 [78 to 195] arbitrary units, p , 0.001). As an indicator of
platelet-monocyte interaction, mean fluorescence of the platelet marker GP Iba in the
monocytes population decreased after abciximab, although it remained unaffected by heparin
alone. Abciximab achieved this effect by a reduction in platelet mass attached to monocytes
(GP Iba fluorescence intensity of heterotypic aggregates at 24 h [arbitrary units]: 187 [143
to 236] after abciximab vs. 228 [156 to 332] after heparin, p 5 0.02), whereas it did not affect
the percentage of monocytes with adherent platelets. Reduction of platelet-monocyte
interaction resulted in decreased Mac-1 surface expression (fluorescence intensity at 24 h
[arbitrary units]: 116 [68 to 153] after abciximab vs. 162 [117 to 239] after heparin, p 5
0.001).
CONCLUSIONS In patients with AMI, platelet-leukocyte interactions modulate Mac-1 expression on
monocytes. Glycoprotein IIb/IIIa blockade is a therapeutic option to interfere with this
mechanism. (J Am Coll Cardiol 1999;34:1420–6) © 1999 by the American College of
Cardiology
A large body of evidence from animal experiments indicates
that the interaction of neutrophils and monocytes with the
microvasculature limits reperfusion in acute myocardial
infarction (AMI) (1–5). In this interaction, the beta2-
integrin Mac-1 plays a pivotal role (1–4). Inhibition of
Mac-1 dependent leukocyte adhesion markedly improves
microvascular reflow and myocardial salvage in animal
models of AMI (1–3). This study as well as other recent
studies have found upregulation of Mac-1 on leukocytes of
patients with AMI (6,7). The underlying mechanism for
this phenomenon remained obscure.
In this study, we hypothesized that platelet-induced
leukocyte activation may play a role in this respect. We
previously described increased platelet leukocyte interaction
in patients with AMI (8). In this interaction, primary
attachment of platelets to myeloid leukocytes occurs by
tethering of the platelet’s P-selectin to P-selectin glycopro-
tein ligand-1 (PSGL-1) on leukocytes (9–14). The hetero-
typic adhesion is stabilized by binding Mac-1 to an un-
known counter-receptor on the platelet (12–15). This is
enabled by Mac-1 activation as a consequence of tyrosine
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phosphorylation and mitogen-activated protein kinase acti-
vation due to PSGL-1 ligation (13,16). As part of this cell
activation, platelet binding to myeloid leukocytes also up-
regulates the magnitude of Mac-1 surface expression on
leukocytes (17,18). The increased platelet leukocyte inter-
action in patients with AMI may thus contribute to the
upregulation of Mac-1 on leukocytes in this condition.
This prospective randomized study investigated platelet-
induced upregulation of Mac-1 and its inhibition by glyco-
protein (GP) IIb/IIIa receptor blockade in patients with
AMI.
METHODS
Study design. We investigated patients in a prospective
randomized trial comparing GP IIb/IIIa receptor blockade
with usual care for stenting in AMI (19). The study
included patients with AMI undergoing revascularization
by stent placement within 48 h after onset of pain. Inclusion
criteria were: 1) typical anginal pain lasting .30 min, 2)
ST-segment elevation of at least 1 mm in two or more
contiguous leads, 3) elevation in creatine kinase to at least
three times the upper limit of normal with a concomitant
rise in MB-isoenzyme, and 4) coronary artery occlusion
with angiographic appearance of fresh thrombus. We re-
cruited patients who met the first criterion and at least one
of the other criteria. Exclusion criteria were inability to give
informed consent and contraindications to one of the study
drugs. By means of sealed envelopes, patients were ran-
domized to one of two open label treatment regimens:
patients assigned to treatment with GP IIb/IIIa receptor
blockade received a bolus of abciximab, 0.25 mg per
kilogram of body weight before the intervention, followed
by continuous infusion, 10 mg per min for 12 h, plus
heparin, 7,500 U. In patients assigned to usual care, we
administered 15,000 units of heparin before the inter-
vention followed by intravenous heparin infusion,
1,000 units/h, for the first 12 h after sheath removal.
All patients received aspirin, 500 mg intravenously, before
catheterization, and postinterventional antithrombotic
therapy consisted of ticlopidine (250 mg bds) and aspirin
(100 mg bds) throughout the study. Stent placement was
performed, as described previously (19). In all patients the
procedure was successful and achieved Thrombolysis in
Myocardial Infarction (TIMI) grade 3 flow.
The study consisted of 50 patients assigned to usual care
and 50 patients assigned to abciximab. The study groups
were homogeneous with respect to baseline demographic,
clinical and angiographic characteristics (Table 1). All
patients gave written informed consent. The study was
carried out according to the Declaration of Helsinki and was
approved by our institutional ethics committee.
Immunostaining and flow cytometry. Blood samples were
obtained before the initiation of in-hospital therapy and
subsequently at 12 h and at days 1, 3, 5 and 10 after
revascularization of the occluded vessel. Samples were col-
lected into a fixative solution (1:3 vol/vol) containing
methacroleine (Cyfix II, gift of Dr. Andreas Ruf, Karlsruhe,
Germany) (20,21). After 10 min samples were diluted in
1:10 (vol/vol) ice-cold phosphate buffered saline (PBS) and
stored at 4°C until staining was performed within 12 h.
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
FITC 5 fluoresceine isothiocyanate
GP 5 glycoprotein
mAbs 5 monoclonal antibodies
PBS 5 phosphate buffered saline
PE 5 phycoerythrine
PSGL 5 P-selectin glycoprotein ligand
Table 1. Baseline Demographic, Clinical and Angiographic
Characteristics of the Study Population
Abciximab
(n 5 50)
Usual Care
(n 5 50)
p
Value
Age (yr) 61.3 6 10.5 62.6 6 10.8 0.6
Women 8 13 0.3
Smoker 30 20 0.1
Hypercholesterolemia 36 32 0.2
Arterial hypertension 29 36 0.2
Diabetes mellitus 4 8 0.4
Multivessel disease 34 34 1.0
Previous CABG 1 2 1.0
Previous PTCA 2 3 1.0
Time from onset
of pain to
intervention
,6 h 17 21
6–12 h 10 9
12–24 h 11 9
24–48 h 12 11
Prior thrombolytic
therapy
10 5 0.3
Killip class 0.5
I 39 42
II 6 2
III 1 2
IV 4 4
TIMI grade 0/1 flow 39 44 0.3
Q-wave MI 38 33 0.3
Target vessel 0.6
LAD 25 21
LCX 7 10
RCA 18 19
Venous bypass
graft
0 0
Peak creatine kinase
(U/liter)
1074 6 1005 1009 6 1115 0.8
Data are expressed as mean value 6 SD or number of patients.
CABG 5 coronary artery bypass graft surgery; LAD 5 left anterior descending
coronary artery; LCx 5 left circumflex coronary artery; RCA 5 right coronary artery.
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Immunostaining and flow cytometry were performed as
previously described (4,8,20). We stained leukocytes in
whole-blood by triple-color immunofluorescence with the
use of fluoresceine isothiocyanat (FITC)-labeled monoclo-
nal antibodies (mAbs) for the alphaM-chain of Mac-1
(CD11b), P-selectin (CD 62P), fragment E epitope of
fibrinogen (all from Immunotech, Hamburg, Germany),
and receptor induced binding site (RIBS neoepitope) on
fibrinogen (gift of Dr. M. Ginsberg), phycoerythrine (PE)-
labeled mAbs for GP Iba of von Willebrand-factor receptor
complex (CD 42b, Immunotech), PE-Cy5-labeled mAbs
for the monocyte marker CD 14 (endotoxin receptor,
Immunotech), quantum red-labeled monoclonal antibodies
(mAbs) for the alphaM-chain of Mac-1 (CD11b, Sigma,
Mu¨nchen, Germany). Preliminary experiments revealed
that binding of the anti-CD11b mAbs used in our study was
not affected by abciximab at doses 10 times the therapeutic
range (50 mg/L). We incubated aliquots of 40 mL with
saturating concentrations of mAbs for 30 min at room
temperature. Thereafter, erythrocytes were lysed with im-
munolyse (Coulter Electronics, Krefeld, Germany).
For flow cytometry, we used a FACS-Calibur (Becton-
Dickinson, Heidelberg, Germany) equipped with a 488-nm
argon laser at 500 mW. We identified myeloid leukocytes as
anti-CD11b-positive events in the histogram generated by
the FITC- or PE-fluorescence and monocytes as anti-
CD14-positive events in the histogram generated by the
PE-Cy5 fluorescence. In the GPIba histogram, GPIba-
positive leukocytes with a fluorescence intensity above that
of an isotype-matched irrelevant control antibody always
could be clearly differentiated from GPIba-negative leuko-
cytes. The mean channel fluorescence intensity was a
measure for antibody binding and, thus, antigen surface
exposure.
In vitro experiments. Blood samples from healthy volun-
teers were anticoagulated in 1:10 (vol/vol) CPDA (citrate
phosphate dextrose adenine) (Greiner) and were incubated
for 15 min with or without 50 mmol/L ADP. In some
experiments, we added blocking anti-P-selectin mAbs
(clone G1, Centocor, Malvern) at a concentration of
10 mg/L or abciximab at a concentration of 50 mg/L before
stimulation with ADP. After incubation, samples were
washed three times with PBS and stained with FITC-
conjugated anti-CD42 and PE-conjugated anti-CD14
mAbs for 30 min at room temperature. We then performed
flow cytometry as described above. In some samples we
confirmed the flow cytometry findings by confocal laser
scanning microscopy (Axiovert35, Zeiss, Oberkochen, Ger-
many), as previously described (17).
Statistical analysis. Discrete variables, expressed as counts,
were tested by Fisher’s exact test. Results of normally
distributed continuous variables were reported as mean 6
standard deviation and were tested by the t test for paired
and unpaired samples, as appropriate. The Kolmogorov-
Smirnov test showed that the flow cytometry data were not
normally distributed. Results are reported as median (inter-
quartile range). Differences between treatment groups were
tested by the Mann-Whitney U test. We first analyzed
differences in the entire time course by testing the sum of
each measurement in a given patient. If this evaluation
revealed significant differences, we compared the variable at
individual time points. Time courses were tested with
Friedman’s test followed by Wilcoxon’s rank sum test. To
corroborate these analyzes, we also performed analysis of
variance (ANOVA) for repeated measure which always
confirmed the results of the nonparametric tests. We used
SPSS 8.01 for Macintosh software package for all statistical
analyses. A p value less than 0.05 in the two-tailed test was
regarded as significant.
RESULTS
Effect of abciximab on platelet-leukocyte interaction in
vitro. After stimulation of whole blood with ADP, almost
80% of myeloid leukocytes had platelets attached (Fig. 1).
Confocal laser microscopy revealed adhesion of platelet
aggregates as the predominant pattern of platelet-leukocyte
interaction (Fig. 2). Abciximab did not affect the percentage
of myeloid leukocytes with adherent platelets but reduced
the intensity of GP Iba immunofluorescence of platelet-
leukocyte aggregates (Fig. 1). On microscopy, attachment of
single platelets was the predominant pattern of platelet-
leukocyte interaction in the presence of abciximab (Fig. 2).
With abciximab, we found a conspicuous reduction in the
amount of platelets attached to myeloid leukocytes as
compared with stimulation in absence of abciximab (Fig. 2).
Blocking P-selectin mAbs completely prevented ADP-
induced platelet-leukocyte interaction (Fig. 1). Stimulation
of whole blood samples with LPS (lipopolysaccharide) at
1 mg/L had no effect on leukocyte-platelet interaction.
Figure 1. Percentage of monocytes with GP Iba fluorescence
signal (left panel) and GP Iba fluorescence intensity (arbitrary
units) (right panel) of GP Iba-positive monocytes in whole blood
at baseline (control) and after stimulation in vitro with 20 mmol/L
ADP in the presence or absence of blocking anti-P-selectin mAbs
or of abciximab. *p , 0.01 for the comparison to ADP-stimulated
whole blood without mAbs. GP 5 glycoprotein; mAbs 5 mono-
clonal antibodies.
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Platelet-leukocyte interaction before intervention. In
patients, analysis of GP Iba immunofluorescence revealed
that 7% (5.1% to 9.1%) of the monocytes and 3.9% (2.9% to
5.2%) of all myeloid leukocytes had platelets attached before
the intervention. Analysis of P-selectin immunofluorescence
in myeloid leukocytes yielded similar percentages of coag-
gregates (4.7% [3.3% to 8.7%]). Mac-1 surface expression
on monocytes with adherent platelets was increased sub-
stantially as compared with that on platelet-negative mono-
cytes (Fig. 3), whereas CD14 did not show significant
differences. The pattern of platelet-dependent Mac-1 sur-
face expression in the entire population of myeloid leuko-
cytes was similar to that in monocytes (Fig. 3). In platelet-
monocyte aggregates, immunofluorescence for bound
fibrinogen (fragment E epitope) was increased compared
with single monocytes (Table 2). Analyzing both fragment
E epitopes and receptor-induced neoepitopes on fibrinogen,
we obtained similar results in the entire myeloid leukocyte
population (Table 2).
Effect of abciximab on platelet-leukocyte interaction in
reperfused AMI. At 24 h and 72 h after the intervention, the
level of platelet-monocyte interaction was significantly lower in
the abciximab group than in the control group (Fig. 4). In the
abciximab group, platelet-monocyte interaction decreased dur-
ing the first 24 h of reperfusion whereas it did not change in
the control group (Fig. 4). Compared with usual care, abcix-
imab did not affect the percentage of monocytes with adherent
platelets (7.2% [5.2% to 8.9%] vs. 6.7% [5% to 9.7%], p 5
0.73) but reduced the amount of platelets incorporated into
platelet-monocyte aggregates. This was shown by a reduction
in the GP Iba immunofluorescence intensity of platelet-
monocyte aggregates (187 [143 to 236] vs. 228 [156 to 332]
arbitrary units, p 5 0.02). Similar to the time course of
platelet-monocyte interaction, we found a decrease in Mac-1
on monocytes within 24 h of reperfusion in the abciximab
group, but an increase in the control group (Fig. 5). At 24 h
and at 72 h after the intervention, Mac-1 surface expression on
monocytes in the abciximab group was significantly lower than
in the control group (Fig. 5). Findings in the entire population
of myeloid leukocytes were similar to those in monocytes
(Table 3). Without affecting the percentage of myeloid leuko-
cytes with adherent platelets, abciximab reduced the platelet
load in platelet-leukocyte aggregates compared with usual care.
Thus, at 24 h after the intervention, surface exposure of the
platelet receptors GP Iba and P-selectin was lower in the
myeloid leukocyte population of the abciximab group than in
that of the usual care group (Table 3). The same was found for
fibrinogen bound to myeloid leukocytes (Table 3). The lower
platelet load in the myeloid leukocyte population of the
abciximab group was associated with a lower surface expression
of Mac-1 at 24 h (Table 3) and at 72 h after the intervention
(85 [56 to 164] vs. 131 [94 to 204], p 5 0.03), compared with
usual care.
DISCUSSION
Our study demonstrates the modulation of Mac-1 expres-
sion on myeloid leukocytes by platelet-leukocyte interac-
tions in patients with AMI. It also indicates that GP
IIb/IIIa blockade is a therapeutic option to interfere with
this mechanism.
Platelet-induced upregulation of Mac-1. Experimental
studies indicate that heterotypic adhesion of platelets and
leukocytes is not just a mere marker of ongoing platelet
activation but also has important consequences for leukocyte
function (8,17,18,22). In vitro, binding of activated platelets
to myeloid leukocytes induces expression of proinflamma-
tory cytokines, oxidative burst and increased surface expres-
sion of Mac-1 (8,17,18,22). Confirming the relevance of
platelet-induced leukocyte activation in vivo, we found that
Mac-1 expression was higher on circulating monocytes and
neutrophils that had platelets attached than it was on
platelet-negative myeloid leukocytes. As a potential expla-
nation for this finding, we can exclude preferential binding
of platelets to preactivated leukocytes. Due to sequestration
Figure 2. Confocal laser microscopic images (upper panels) and
corresponding P-selectin fluorescence images (lower panels) of
platelet-leukocyte aggregates after in vitro stimulation of whole
blood with 20 mmol/L ADP in the presence or absence of
abciximab.
Figure 3. Mac-1 fluorescence intensity of leukocytes with platelets
attached (GP Iba 1) of platelet-negative leukocytes (GP Iba 2)
in the monocyte population and in the entire population of
myeloid leukocytes (All). GP 5 glycoprotein.
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of surface exposed PSGL-1 (23), leukocyte preactivation
either does not enhance or even decreases platelet-leukocyte
interaction as shown in this study and in previous studies
(23,24).
Increased adhesiveness of platelet-leukocyte aggregates.
Compared with platelet-negative cells, the adhesive prop-
erties of platelet-leukocyte aggregates are markedly en-
hanced. Apart from increased levels of Mac-1, they are
endowed with the entire arsenal of platelet adhesion. As
shown by our study, this includes von Willebrand-factor
receptor, mediating adhesion to subendothelial structures
under high shear (25), P-selectin, involved in interactions
with endothelial cells (5,26) and receptor bound fibrinogen.
Receptor bound fibrinogen has the ability to bind nonacti-
vated GP IIb/IIIa and to induce activation of resting
platelets by outside-in integrin signaling (27). This is an
important mechanism for the recruitment of circulating
platelets to the site of vascular injury (27). In addition,
monocytes promote thrombin formation by surface expo-
sure of tissue factor that is also increased in AMI (6).
Platelet-monocyte aggregates, therefore, constitute an ideal
nidus for intravascular thrombus formation (28).
Effect of abciximab. Several independent studies suggested
that GP IIb/IIIa is not involved in the interaction of
activated platelets to myeloid leukocytes (11,13–15,29).
Nevertheless, abciximab may interfere with the formation of
platelet-monocyte aggregates in at least two ways: 1) due to
its cross-reactivity with Mac-1 (30), abciximab may inhibit
the stabilization of platelet-leukocyte aggregates by binding
Mac-1 to an unknown counter-receptor on the platelet, 2)
abciximab prevents the formation and, hence, attachment of
platelet aggregates, thereby reducing the platelet mass in the
heterotypic aggregates. Our study suggests that only the
latter mechanism is relevant. In both our in vitro experi-
ments as well as in blood samples taken from patients with
AMI, abciximab reduced platelet-leukocyte interaction by
reducing the platelet mass in platelet-monocyte aggregates
while the percentage of monocytes with platelets attached
remained unchanged. These findings by flow cytometry
were also confirmed by laser scanning microscopy.
Abciximab substantially reduced Mac-1 surface expres-
sion on myeloid leukocytes compared with conventional
heparin treatment. Our preliminary experiments ensured
that abciximab did not affect the recognition of Mac-1 by
Figure 4. Overall GP Iba fluorescence intensity (arbitrary units) of
monocytes in patients assigned to heparin treatment (closed
circles) and in patients assigned to abciximab (open circles).
Circles represent median and error bars interquartile range. *p ,
0.002 for the comparison between groups. p Values for the
comparison with the initial value in each treatment group are given
at the bottom and at the top of the graphs. GP 5 glycoprotein.
Figure 5. Mac-1 fluorescence intensity (arbitrary units) of mono-
cytes in patients assigned to heparin treatment (closed circles) and
in patients assigned to abciximab (open circles). Circles represent
median and error bars interquartile range. *p , 0.004 for the
comparison between groups. p Values for the comparison with the
initial value in each treatment group are given at the bottom and
at the top of the graph.
Table 2. Fibrinogen Binding on Single Myeloid Leukocytes (GP Iba 2) and on
Platelet-Leukocyte Aggregates (GP Iba 1)
GP Iba 2 GP Iba 1 p Value
Entire population
Fibrinogen fluorescence intensity 31 (25,43) 240 (147,459) p , 0.001
RIBS fluorescence intensity 21 (16,26) 185 (132,332) p , 0.001
Monocytes
Fibrinogen fluorescence intensity 20 (15,29) 532 (248,958) p , 0.001
Data are expressed as median (quartiles). Fluorescence intensity is expressed in arbitrary units.
RIBS 5 receptor induced binding sites on fibrinogen.
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the mAbs used in our study. We, thus, attribute the reduced
Mac-1 surface expression after treatment with abciximab to
the reduction in the mass of platelets attached to myeloid
leukocytes. This could have led to less paracrine or direct
receptor stimulation of leukocytes (16,29). The reduction in
Mac-1 surface expression by abciximab supports the concept
that platelet-leukocyte interactions contribute to the up-
regulation of Mac-1 expression in patients with AMI.
Reduction by abciximab in platelet-leukocyte interaction
and leukocyte Mac-1 surface exposure became apparent at
the first sampling after initiation of therapy and persisted
during the first three days. This is consistent with the
durable receptor occupancy and inhibition of platelet aggre-
gation by abciximab, even after discontinuation of the
infusion (20). In addition, the observed long-lasting effect of
abciximab may be related to plaque passivation due to
adhesion of platelets with blocked GP IIb/IIIa receptors.
This could have reduced ongoing platelet activation at the
treated plaque (31).
Methodologic considerations and study limitations. To
avoid ex vivo platelet-leukocyte interaction, we drew blood
samples directly into Cyfix II, a fixative solution developed
for flow cytometry. Previous studies verified that, after
fixation with Cyfix II, mAb binding remains adequate and
allows detection of subtle changes in the expression of
activation-dependent cell surface markers (20,21).
Our study did not address consequences of platelet-
induced leukocyte activation apart from Mac-1 surface
expression. Nevertheless, it is tempting to speculate that the
reduction in platelet-leukocyte interaction by abciximab
could have reduced oxidative burst and cytokine elaboration,
which are also stimulated by platelet adhesion (8,17,18,22).
Implications. As indicated by the surface exposure of von
Willebrand-factor receptor, P-selectin and receptor-bound
fibrinogen, the platelet-leukocyte aggregates formed under
treatment with abciximab were less bulky and less adhesive
than those under standard heparin (5,25–27). Moreover, the
decreased platelet-leukocyte interaction under abciximab led
to downregulation of the surface expression of Mac-1. Our
findings, thus, elucidate a novel mechanism by which
abciximab can reduce the interaction of platelet-leukocyte
aggregates with the microvasculature and limit inflamma-
tory responses during reperfusion in AMI. Therefore, ab-
ciximab may help to optimize reperfusion at the microvas-
cular level.
Consistent with this inference, we recently found that,
compared with standard heparin treatment, abciximab sub-
stantially improved microvascular flow after stent placement
in AMI (19). This benefit was functionally relevant as it
conferred increased recovery of contractile function in the
area at risk (19). This study suggests that reduction of bulky,
adhesive platelet-leukocyte aggregates may have contributed
to the beneficial effect of abciximab during reperfusion in
AMI.
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